ResMed Inc
RMD: XNYS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| ?Kx | LOCK|<&q& | LOCK|#q!xrpJ |
ResMed Earnings: Volume Drives Solid Start, but Some Earnings Benefits Will Reverse
ResMed’s fiscal first-quarter 2027 revenue rose 6% to USD 1.41 billion, while EPS increased 14% to USD 2.91. Gross margin expanded 50 basis points to 62.5% on manufacturing productivity gains and delayed US facility costs. Management reiterated its fiscal 2027 guidance.
